Llwytho...
Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | EJNMMI Res |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer Berlin Heidelberg
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365580/ https://ncbi.nlm.nih.gov/pubmed/30725219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-019-0484-y |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|